Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
A study in Chile with 10.2 million participants assessed the effectiveness of the inactivated SARS-CoV-2 (CoronaVac) vaccine, developed in China. Efficacy among fully vaccinated subjects was estimated at 65.9% protection against symptomatic COVID-19.
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
The safety profile clearly suggests that the risk of adverse events is much higher after SARS-CoV-2 infection than after receiving the BNT162b2 mRNA vaccine (Pfizer-BioNTech).
The 2020 EMBL-EBI Annual Report
The 2020 EMBL-EBI Annual Report provides facts and figures on the use of EMBL-EBI resources. One of the activities undertaken by the EMBL-EBI was the launch of the European COVID-19 Data Platform.
Professor Krzysztof Pyrć from the Jagiellonian University is among the experts on SARS-CoV-2 variants appointed by the European Commission
The task of the expert group will be to establish criteria for the identification of variants of concern (VOC) and variants under investigation (VUI) of the SARS-CoV-2 to adapt vaccines
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
British study compared the effectiveness of the BioNTech-Pfizer and AstraZeneca vaccines against the Alfa and Delta variants of the SARS-CoV-2 virus in symptomatic individuals with COVID-19.
Mapping the human genetic architecture of COVID-19
Research published in Nature found 13 important loci in the human genome that are associated with SARS-CoV-2 infection or COVID-19 severity. The results are based on a meta-analysis of the genetic data of nearly 50,000 COVID-19 patients and 2 million controls from 19 countries. The research is part of the